Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4877360 | 0.90 | KDM4E (0.37) | KDM4ESMN1; SMN2GRIN2BBRD4CREBBP | |
| SCHEMBL4877246 | 0.88 | KCNH2 (0.34) | GRIN2BBRD4CREBBPGRM5 | |
| SCHEMBL14269777 | 0.87 | SMN1; SMN2 (0.31) | KDM4ESMN1; SMN2 | |
| SCHEMBL4876431 | 0.87 | GRM5 (0.34) | KDM4ESMN1; SMN2GRIN2BGRM5 | |
| SCHEMBL4878287 | 0.87 | POLB (0.41) | KDM4ESMN1; SMN2GRIN2B | |
| SCHEMBL4867721 | 0.86 | CBX7 (0.38) | KDM4ESMN1; SMN2GRIN2BBRD4CREBBP | |
| SCHEMBL4876725 | 0.83 | KMT2A (0.41) | SMN1; SMN2GRIN2B | |
| SCHEMBL4875250 | 0.83 | KMT2A (0.41) | SMN1; SMN2GRIN2B | |
| SCHEMBL4868476 | 0.81 | GRIN2B (0.40) | KDM4ESMN1; SMN2GRIN2BGRM5 | |
| SCHEMBL4877153 | 0.80 | GRIN2B (0.40) | GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051384-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | KDM4E 3075/4885SMN1; SMN2 1929/4885GRIN2B 3420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.